Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
A study published in a recent issue of the journal Lupus characterizes a new potential biomarker of fatigue in people with lupus.
People with lupus may experience chronic fatigue, the exact causes of which are yet to be fully understood. There are a number of different energy-producing metabolic processes that may be affected in people with lupus.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.
The researchers hoped to determine whether children with lupus have worse academic functioning relative to their peers of similar demographic and socioeconomic background.
Scientists could be a step closer to identifying and treating early cases of lupus, before the onset of organ-damaging illness.
This study examined the relationship between fluctuating levels of vitamin D during different seasons, characterized by differing amounts of light exposure, while patients experienced lupus flares.
This study examined the long-term safety of belimumab over a 4-year period in people with lupus. The results highlight the long-term safety of belimumab over a 4-year period.